Stock listing
NASDAQ:CNSP CNS Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of CNS Pharmaceuticals, Inc.
Follow CNS Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CNSP
$3.56 USD -0.88 (-19.8%)
Close on Nov 20, 2026
- Day range
- $3.56 – $3.68 USDNov 20, 2026
- Volume
- 666 sharesNov 20, 2026
- Market cap
- $5.25M USDAt the close on Nov 20, 2026 · price × 1.48M shares outstanding
- 52-week range
- $1.90 – $10.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $45,536 USDMedian day 4,400 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CNSP · Home | $3.56 USD | -0.88 (-19.8%) | 666 | $3.678 | $3.678 | $3.56 | $4.44 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CNSP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.56 | -0.88 | -19.8% | $3.678 | $3.678 | $3.56 | 666 | |
| $4.44 | +0.29 | +7.0% | $4.18 | $4.44 | $4.16 | 3,184 | |
| $4.15 | +0.67 | +19.3% | $3.59 | $4.395 | $3.44 | 8,311 | |
| $3.48 | +0.59 | +20.4% | $3.14 | $3.547 | $2.96 | 28,735 | |
| $2.89 | -0.73 | -20.2% | $3.70 | $3.70 | $2.89 | 18,100 | |
| $3.62 | 0.00 | 0.0% | $3.70 | $3.70 | $3.62 | 2,800 | |
| $3.62 | -0.23 | -6.0% | $4.045 | $4.07 | $3.62 | 4,400 | |
| $3.85 | -0.09 | -2.3% | $3.98 | $3.98 | $3.77 | 5,900 | |
| $3.94 | +0.02 | +0.5% | $4.091 | $4.175 | $3.90 | 5,900 | |
| $3.92 | -0.09 | -2.2% | $4.05 | $4.26 | $3.894 | 8,400 | |
| $4.01 | -0.33 | -7.6% | $4.07 | $4.11 | $4.00 | 3,400 | |
| $4.34 | -0.21 | -4.6% | $4.39 | $4.39 | $4.06 | 4,000 | |
| $4.55 | +0.16 | +3.6% | $4.40 | $4.70 | $4.00 | 13,900 | |
| $4.39 | -0.61 | -12.2% | $5.00 | $5.00 | $4.296 | 15,100 | |
| $5.00 | +0.23 | +4.8% | $4.60 | $5.01 | $4.25 | 52,900 | |
| $4.77 | +0.26 | +5.8% | $4.60 | $5.19 | $4.35 | 46,400 | |
| $4.51 | -0.57 | -11.2% | $4.50 | $5.37 | $4.30 | 61,100 | |
| $5.08 | +0.455 | +9.8% | $4.68 | $5.45 | $4.11 | 75,400 | |
| $4.625 | -0.345 | -6.9% | $4.755 | $4.755 | $4.525 | 2,200 | |
| $4.97 | +0.22 | +4.6% | $4.50 | $5.00 | $3.67 | 6,000 | |
| $4.75 | -0.075 | -1.6% | $4.75 | $4.95 | $3.98 | 10,000 | |
| $4.825 | -0.165 | -3.3% | $4.825 | $4.825 | $4.825 | 300 | |
| $4.99 | 0.00 | 0.0% | $4.99 | $4.99 | $4.99 | 0 | |
| $4.99 | +0.139 | +2.9% | $4.85 | $5.00 | $4.755 | 5,600 | |
| $4.851 | -0.326 | -6.3% | $4.98 | $5.00 | $4.65 | 13,400 | |
| $5.177 | -0.173 | -3.2% | $5.177 | $5.177 | $5.177 | 900 | |
| $5.35 | 0.00 | 0.0% | $5.35 | $5.35 | $5.35 | 655 | |
| $5.35 | +0.16 | +3.1% | $5.13 | $5.40 | $5.00 | 14,200 | |
| $5.19 | -0.16 | -3.0% | $5.34 | $5.40 | $5.03 | 6,200 | |
| $5.35 | 0.00 | 0.0% | $5.35 | $5.35 | $5.34 | 1,200 | |
| $5.35 | -0.08 | -1.5% | $5.36 | $5.36 | $5.35 | 1,800 | |
| $5.43 | +0.128 | +2.4% | $5.35 | $5.44 | $5.082 | 2,700 | |
| $5.302 | +0.002 | 0.0% | $5.40 | $5.45 | $5.302 | 6,200 | |
| $5.30 | -0.025 | -0.5% | $5.50 | $5.50 | $5.30 | 2,000 | |
| $5.325 | +0.085 | +1.6% | $5.23 | $5.40 | $5.11 | 10,900 | |
| $5.24 | -0.06 | -1.1% | $5.35 | $5.35 | $5.24 | 900 | |
| $5.30 | +0.393 | +8.0% | $5.25 | $5.475 | $4.93 | 8,000 | |
| $4.907 | -0.203 | -4.0% | $4.907 | $4.907 | $4.907 | 500 | |
| $5.11 | +0.179 | +3.6% | $4.982 | $5.11 | $4.97 | 2,400 | |
| $4.931 | -0.219 | -4.3% | $5.21 | $5.21 | $4.931 | 1,300 | |
| $5.15 | 0.00 | 0.0% | $5.15 | $5.15 | $5.15 | 1,800 | |
| $5.15 | -0.089 | -1.7% | $5.15 | $5.15 | $5.15 | 2,900 | |
| $5.239 | +0.02 | +0.4% | $5.245 | $5.245 | $5.00 | 2,700 | |
| $5.219 | +0.109 | +2.1% | $5.12 | $5.50 | $5.12 | 2,300 | |
| $5.11 | -0.01 | -0.2% | $5.12 | $5.12 | $5.06 | 4,400 | |
| $5.12 | -0.38 | -6.9% | $5.35 | $5.35 | $5.05 | 2,600 | |
| $5.50 | -0.20 | -3.5% | $5.54 | $5.54 | $5.50 | 3,900 | |
| $5.70 | 0.00 | 0.0% | $5.70 | $5.70 | $5.70 | 2,000 | |
| $5.70 | -0.14 | -2.4% | $5.70 | $5.70 | $5.70 | 1,000 | |
| $5.84 | +0.09 | +1.6% | $5.845 | $5.845 | $5.73 | 18,500 | |
| $5.75 | -0.03 | -0.5% | $5.79 | $5.79 | $5.75 | 1,600 | |
| $5.78 | -0.16 | -2.7% | $5.89 | $5.94 | $5.76 | 2,700 | |
| $5.94 | +0.21 | +3.7% | $5.64 | $5.99 | $5.64 | 10,600 | |
| $5.73 | -0.157 | -2.7% | $5.86 | $5.916 | $5.73 | 4,800 | |
| $5.887 | -0.123 | -2.0% | $6.00 | $6.00 | $5.60 | 1,700 | |
| $6.01 | +0.118 | +2.0% | $5.91 | $6.01 | $5.745 | 19,700 | |
| $5.892 | -0.088 | -1.5% | $5.77 | $5.892 | $5.77 | 1,700 | |
| $5.98 | +0.457 | +8.3% | $5.63 | $5.98 | $5.61 | 5,100 | |
| $5.523 | +0.006 | +0.1% | $5.70 | $5.79 | $5.477 | 3,700 | |
| $5.517 | +0.077 | +1.4% | $5.57 | $5.80 | $5.50 | 7,200 | |
| $5.44 | -0.36 | -6.2% | $5.80 | $5.81 | $5.44 | 7,000 | |
| $5.80 | -0.14 | -2.4% | $5.74 | $6.05 | $5.739 | 8,600 | |
| $5.94 | +0.11 | +1.9% | $5.71 | $6.19 | $5.60 | 18,800 | |
| $5.83 | -0.17 | -2.8% | $5.965 | $6.05 | $5.83 | 8,000 | |
| $6.00 | +0.17 | +2.9% | $5.71 | $6.076 | $5.71 | 4,100 |
Splits
4 splits since 2022 · NASDAQ:CNSP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-30 | Consolidation |
- Ticker
- NASDAQ:CNSP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
Latest deck · Jul 2, 2026
Investor Presentation (July 2026)
Investor deck · 12 slides
Latest news
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
Nov 16, 2026
Closed $3.48 (+20.4%) on Nov 16, 2026
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
Sep 1, 2026
Closed $5.89 (-1.5%) on Sep 1, 2026
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
Aug 27, 2026
Closed $5.52 (+1.4%) on Aug 27, 2026
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
Aug 12, 2026
Closed $5.01 (-2.3%) on Aug 12, 2026
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation
Jun 9, 2026
Closed $4.59 (-6.1%) on Jun 9, 2026
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Jun 8, 2026
Closed $4.89 (-2.2%) on Jun 8, 2026
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
May 20, 2026
Closed $5.10 (+6.7%) on May 20, 2026
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
May 14, 2026
Closed $5.01 (-9.2%) on May 14, 2026
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
May 4, 2026
Closed $7.84 (+239.2%) on May 4, 2026
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Mar 11, 2026
Closed $2.96 (-11.6%) on Mar 11, 2026
CNS Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 172 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 24 decks · latest Jul 2, 2026
Where CNS Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CNSP · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CNSP | BOATS | United States | USD |
| Frankfurt:BE50 | Frankfurt | Germany | EUR |
Valuation
Price/book 0.3× against a median of 1.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$11.96M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.74
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. · NASDAQ:CNSP | US$5.25M | −US$11.96M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.74 |
| Theriva Biologics, Inc. · AMEX:TOVX | US$5.51M | US$461,120 | n/a | n/a | n/a | 0.5× | n/a | 0.3× | 2.65 |
| Hemostemix Inc · TSXV:HEM | US$5.35M | US$7.70M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Curative Biotechnology Inc · OTC:CUBT | US$5.34M | US$6.55M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| Abpro Holdings, Inc. · OTC:ABPO | US$5.31M | US$1.07M | 2.6× | n/a | n/a | n/a | n/a | n/a | -0.79 |
| Soligenix, Inc. · NASDAQ:SNGX | US$5.14M | −US$3.61M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.76 |
| Rakovina Therapeutics Inc · TSXV:RKV | US$5.10M | US$7.20M | n/a | n/a | n/a | n/a | n/a | n/a | -0.43 |
| StimCell Energetics Inc. · OTC:STME | US$5.10M | US$5.09M | n/a | n/a | n/a | n/a | n/a | n/a | 0.99 |
| Longeveron Inc. · NASDAQ:LGVN | US$5.05M | −US$1.78M | n/a | −1.5× | n/a | 1.1× | n/a | 0.1× | 1.55 |
| Oncodesign Precision Medicine S.A. · EURONEXT:ALOPM | US$5.04M | US$8.61M | 0.8× | 30.0× | 0.9× | 1.2× | n/a | 1.6× | n/a |
| Patrys Limited · ASX:PAB | US$4.96M | US$4.47M | n/a | 8.2× | n/a | 10.2× | −363.7% | 0.0× | n/a |
| Median of the others | US$5.12M | US$4.78M | 1.7× | 8.2× | 0.9× | 1.1× | −363.7% | 0.1× | 1.13 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.65 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Rami Levin | President & Chief Executive Officer |
| Steve O’Loughlin | Chief Financial Officer |
| Dylan Wenke | Chief Business Officer |
| Eric Faulkner | Chief Technology Officer |
| Lynne Kelley | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Faith Charles | Chair |
| Amy Mahery | Director |
| Bettina M. Cockroft | Director |
| Jeffry R. Keyes | Director |
| Michal Fisher | Director |
| Rami Levin | President & Chief Executive Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 | +43.6% |
| Q2 2026 | Aug 12, 2026 · Before open | −2.3% |
| Q4 2025 | Mar 31, 2026 · After close | −4.8% |
| Q3 2025 | Nov 14, 2025 · After close | −2.9% |
| Q2 2025 | Aug 14, 2025 · After close | −15.6% |
| Q1 2025 | May 15, 2025 · After close | +1.6% |
| Q4 2024 | Mar 31, 2025 · Before open | +4.6% |
| Q3 2024 | Nov 14, 2024 · After close | −11.8% |
| Q2 2024 | Aug 14, 2024 · After close | +1.4% |
| Q1 2024 | May 15, 2024 · After close | +12.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 14, 2024 | −7.8% |
| Q3 2023 | Nov 14, 2023 · After close | +15.0% |
| Q2 2023 | Aug 14, 2023 · Before open | −12.8% |
| Q1 2023 | May 15, 2023 · Before open | +0.7% |
| Q4 2022 | Mar 31, 2023 · After close | −2.0% |
| Q3 2022 | Nov 10, 2022 · After close | +1.6% |
| Q2 2022 | Aug 12, 2022 · After close | +1.2% |
| Q1 2022 | May 13, 2022 · After close | −2.1% |
| Q4 2021 | Mar 3, 2022 · Before open | +10.3% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 12 slides | Jul 2, 2026 |
| Investor Presentation (March 2026) | Investor deck | 12 slides | March 2026 |
| Investor Presentation (September 2025) | Investor deck | 20 slides | September 2025 |
| Investor Presentation (July 2025) | Investor deck | 20 slides | Jul 15, 2025 |
| Investor Presentation (April 2025) | Investor deck | 21 slides | April 2025 |
| Investor Presentation (February 2025) | Investor deck | 23 slides | February 2025 |
| Investor Presentation (January 2025) | Investor deck | 23 slides | Jan 3, 2025 |
| Investor Day (December 2024) | Investor day | 44 slides | Dec 11, 2024 |
| Investor Presentation (October 2024) | Investor deck | 17 slides | October 2024 |
| Investor Presentation (April 2024) | Investor deck | 19 slides | Apr 15, 2024 |
All 24 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2022) | Investor deck | 19 slides | Jan 10, 2022 |
| Investor Presentation (December 2021) | Investor deck | 23 slides | Dec 3, 2021 |
| Investor Presentation (July 2021) | Investor deck | 19 slides | Jul 19, 2021 |
| Investor Presentation (May 2021) | Investor deck | 19 slides | May 18, 2021 |
| Investor Presentation (March 2021) | Investor deck | 19 slides | Mar 17, 2021 |
| Investor Presentation (February 2021) | Investor deck | 26 slides | Feb 25, 2021 |
| Investor Presentation (December 2020) | Investor deck | 26 slides | Dec 11, 2020 |
| Investor Presentation (September 2020) | Investor deck | 23 slides | Sep 16, 2020 |
| Investor Presentation (June 2020) | Investor deck | 23 slides | Jun 25, 2020 |
| Investor Presentation (March 2020) | Investor deck | 23 slides | Mar 10, 2020 |
| Investor Presentation (January 2020) | Investor deck | 22 slides | Jan 13, 2020 |
| IPO Roadshow (October 2019) | IPO roadshow | 39 slides | Oct 15, 2019 |
| IPO Roadshow (October 2019) | IPO roadshow | 39 slides | Oct 10, 2019 |
| IPO Roadshow (July 2019) | IPO roadshow | 37 slides | Jul 16, 2019 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$22.5M · US$2.3 a share · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Buyers: ADAR1 Capital; Ikarian Capital; Stonepine Capital Management; Nazare Partners Use of proceeds: To identify, acquire and advance differentiated clinical assets, plus working capital and general corporate purposes | May 4, 2026 |
| Public offering of shares of common stock and Series F common stock purchase warrants Closed: US$5M raised · US$1.265 a share · Warrants at US$1.14 for 60 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Together with cash on hand, to fund planned operations into the second half of 2026 | May 16, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 a share on Nov 7, 2019.
- Price
- US$4.00 a share
- Shares offered
- 2,125,000 shares of common stock
- Offering size
- US$850,000
- Underwriters' option
- Up to 318,750 more shares
- Listing
- CNSP on the Nasdaq Capital Market
- Shares delivered
- On or about Nov 13, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 28, 2019 |
| Filed publicly | Jun 28, 2019 |
| Amended 3 times | Newest Oct 7, 2019 |
| Shares registered with an exchange | Nov 5, 2019 |
| Declared effective by the SEC | Nov 7, 2019 |
| Final prospectus, with the price | Nov 8, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 8, 2019 |
| EFFECT · Notice that a registration is effective | Nov 7, 2019 |
| CERT · Exchange's certificate of listing | Nov 6, 2019 |
| CORRESP · Letter to the SEC | Nov 5, 2019 |
| CORRESP · Letter to the SEC | Nov 5, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 5, 2019 |
| FWP · Free writing prospectus | Oct 15, 2019 |
| FWP · Free writing prospectus | Oct 10, 2019 |
| S-1/A · Registration statement, amended | Oct 7, 2019 |
| S-1/A · Registration statement, amended | Aug 22, 2019 |
All 18 filings
| Filing | Filed |
|---|---|
| FWP · Free writing prospectus | Jul 16, 2019 |
| CORRESP · Letter to the SEC | Jul 16, 2019 |
| S-1/A · Registration statement, amended | Jul 16, 2019 |
| UPLOAD · Letter from the SEC | Jul 10, 2019 |
| S-1 · Registration statement | Jun 28, 2019 |
| CORRESP · Letter to the SEC | Jun 28, 2019 |
| UPLOAD · Letter from the SEC | Apr 24, 2019 |
| DRS · Draft registration statement | Mar 28, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 8, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 3.31K | 4.13K | 11.8K | 13.1K | 11.1K | 1.96K | |||
| Gross profit | -3.31K | -4.13K | -11.8K | -13.1K | -11.1K | -1.96K | |||
| Research and development | 9.77M | 9.29M | 14.1M | 9.30M | 9.81M | 5.06M | 1.85M | 21.3K | 32.6K |
| Selling, general and administrative | 6.21M | 5.61M | 4.77M | 5.97M | 4.68M | 4.39M | 1.98M | 860.5K | 437.9K |
| Operating income | -16.0M | -14.9M | -18.9M | -15.3M | -14.5M | -9.45M | -3.83M | -881.8K | -516.3K |
| Depreciation and amortization | 3.92K | 3.31K | 4.13K | 11.8K | 13.1K | 11.1K | 1.96K | 0 | 2.34K |
| EBITDA | -16.0M | -14.9M | -18.9M | -15.3M | -14.5M | -9.44M | -3.83M | -881.8K | -513.9K |
| Interest expense | 15.2K | 16.1K | 13.8K | 7.03K | 9.29K | 3.26K | 26.2K | 28.6K | 4.26K |
| Income before tax | -15.9M | -14.9M | -18.9M | -15.3M | -14.5M | -9.46M | -3.88M | -7.39M | -219.4K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -516.3K |
| Net income | -15.9M | -14.9M | -18.9M | -15.3M | -14.5M | -9.46M | -3.88M | -7.39M | -526.5K |
| Earnings per share, basic | -35.75 | -466.89 | -12,509.11 | -11.22 | -16.50 | -0.57 | -0.28 | -0.70 | |
| Earnings per share, diluted | -35.75 | -466.89 | -12,509.11 | -11.22 | -16.50 | -0.57 | -0.28 | -0.70 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.20M | 6.46M | 548.7K | 10.1M | 5.00M | 14.0M | 7.24M | 282.7K | 110.5K |
| Receivables | 0 | 882.5K | 0 | ||||||
| Current assets | 8.10M | 8.66M | 1.59M | 12.6M | 7.48M | 15.5M | 7.89M | 588.1K | 162.2K |
| Property, plant and equipment | 18.0K | 6.00K | 4.93K | 5.66K | 16.1K | 23.4K | 18.2K | 0 | |
| Goodwill | 334.1K | ||||||||
| Total assets | 8.62M | 8.70M | 1.70M | 13.1M | 8.76M | 15.9M | 7.91M | 683.3K | 162.2K |
| Accounts payable | 3.77M | 2.20M | 5.83M | 3.68M | 1.98M | 946.3K | 243.7K | 128.1K | 57.5K |
| Current liabilities | 4.10M | 2.52M | 6.13M | 4.92M | 2.59M | 1.91M | 311.0K | 1.23M | 220.7K |
| Total debt | 328.6K | 326.1K | 300.8K | 410.0K | 387.8K | 439.3K | 316.9K | 121.8K | |
| Total liabilities | 4.10M | 2.52M | 6.13M | 4.92M | 2.59M | 1.91M | 311.0K | 1.23M | 220.7K |
| Shareholders' equity | 4.52M | 6.18M | -4.43M | 8.13M | 6.16M | 13.9M | 7.60M | -549.3K | -58.5K |
| Shares outstanding | 632.5K | 117.8K | 2.49K | 1.62M | 949.1K | 23.9M | 16.5M | 16.5M | 18 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13.8M | -17.1M | -14.1M | -10.6M | -13.5M | -7.32M | -3.55M | -716.4K | -112.2K |
| Capital spending | -18.2K | -4.19K | -3.90K | -4.42K | -5.75K | -17.9K | -20.1K | 0 | -3 |
| Free cash flow | -13.8M | -17.1M | -14.1M | -10.6M | -13.5M | -7.34M | -3.57M | -716.4K | -112.2K |
| Cash from investing | -18.2K | -4.19K | -3.90K | -4.42K | -5.75K | -17.9K | -20.1K | 0 | -20.1K |
| Cash from financing | 14.6M | 23.0M | 4.64M | 15.6M | 4.51M | 14.1M | 10.3M | 1.16M | 222.7K |
| Share buybacks | -2.04K | 0 | 14.2M | 10.3M | 390.5K | 100.9K | |||
| Change in cash | 739.6K | 5.91M | -9.51M | 5.05M | -9.03M | 6.80M | 6.69M | 444.6K | 110.5K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 2, 2026 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Aug 25, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 21, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | May 27, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 26, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 22, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| D | May 19, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 19, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Material contract | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 17, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 17, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 21, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 12, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 4, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Oct 27, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 24, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 10, 2025 | Meeting notice | SEC |
| 424B5 · Prospectus | Sep 19, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 22, 2025 | Current report | SEC |
| 8-K · Current report | Jul 15, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Material contract | SEC |
| 424B4 · Prospectus | May 14, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 12, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 12, 2025 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| CORRESP · Letter to the SEC | Apr 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 14, 2025 | Other filings | SEC |
| S-1 · Registration statement | Apr 14, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 11, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| DRSLTR · Letter to the SEC with a draft | Apr 7, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Apr 7, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Mar 20, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 8-K · Current report | Feb 21, 2025 | Current report | SEC |
| 8-K · Current report | Jan 3, 2025 | Current report | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| 8-K · Current report | Dec 2, 2024 | Meeting outcome | SEC |
| DEFR14A | Nov 15, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 1, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Oct 28, 2024 | Meeting notice | SEC |
| 8-K · Current report | Oct 24, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 24, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 23, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 15, 2024 | Meeting notice | SEC |
| 8-K · Current report | Sep 18, 2024 | Current report | SEC |
| 8-K · Current report | Sep 12, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 6, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 5, 2024 | Other filings | SEC |
| SC 13D · Big-stake notice | Aug 2, 2024 | Big-stake notice | SEC |
| RW · Request to withdraw a registration | Jul 31, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jul 30, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| 8-K · Current report | Jul 30, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jul 26, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 26, 2024 | Material contract | SEC |
| 8-K · Current report | Jul 24, 2024 | Current report | SEC |
| S-1/A · Registration statement, amended | Jul 19, 2024 | Offer document | SEC |
| S-1 · Registration statement | Jul 12, 2024 | Offer document | SEC |
| 8-K/A · Current report, amended | Jul 11, 2024 | Current report | SEC |
| 8-K · Current report | Jul 9, 2024 | Current report | SEC |
| 424B5 · Prospectus | Jul 5, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 3, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Jul 2, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jun 27, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Jun 25, 2024 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Jun 20, 2024 | Current report | SEC |
| 424B5 · Prospectus | Jun 17, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 14, 2024 | Material contract | SEC |
| S-1 · Registration statement | Jun 7, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 5, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 20, 2024 | Other filings | SEC |
| 8-K · Current report | May 16, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | May 15, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 15, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 9, 2024 | Offer document | SEC |
| 8-K · Current report | May 7, 2024 | Current report | SEC |
| 8-K · Current report | May 3, 2024 | Management or board change | SEC |
| 8-K · Current report | Apr 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| DEF 14A · Proxy statement | Apr 9, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 28, 2024 | Meeting notice | SEC |
| 8-K · Current report | Feb 27, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 21, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Jan 31, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 24, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 24, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 23, 2024 | Management or board change | SEC |
| S-1/A · Registration statement, amended | Jan 22, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 18, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 18, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 16, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 10, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 26, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 26, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 21, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 21, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 21, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 21, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 21, 2023 | Current report | SEC |
| CORRESP · Letter to the SEC | Dec 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 20, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 18, 2023 | Current report | SEC |
| CORRESP · Letter to the SEC | Dec 14, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 14, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 13, 2023 | Other filings | SEC |
| S-1 · Registration statement | Dec 8, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 1, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Nov 30, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 28, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 28, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 21, 2023 | Offer document | SEC |
| S-3 · Registration statement | Nov 20, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 15, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 18, 2023 | Current report | SEC |
| 8-K · Current report | Oct 17, 2023 | Material contract | SEC |
| 4/A · Change in ownership, amended | Oct 12, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Oct 12, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Oct 12, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Oct 12, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Oct 12, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2023 | Insider trade | SEC |
This page holds 200 of 391 filings. Open Filings
Cap table
Built by 6ix from CNS Pharmaceuticals, Inc.’s releases · as of Nov 15, 2026
- Common shares
- 1,475,699
- Fully diluted
- 1,475,699
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,475,699 | Nov 15, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.14 · expire about May 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 15, 2026 | 1,475,699 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Climaco Other companies: Moleculin Biotech, Inc. (Director · Since at least Jul 24, 2017); Essex Rental Corp (Director · Oct 1, 2015 – Oct 1, 2015 · Past); Perma-Fix Environmental Services, Inc. (Director · Jul 1, 2015 – Jul 1, 2015 · Past) | Chief Executive Officer, Director · Since at least Nov 7, 2019 |
| Bettina M. Cockroft Other companies: Annexon, Inc. (BOARD MEMBER · Since at least Jun 5, 2025) | Director · Since at least Nov 17, 2025 |
| Faith L. Charles Other companies: Abeona Therapeutics Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Dec 17, 2025 |
| Jeffry R. Keyes Other companies: Quantum-Si Incorporated (Chief Financial Officer · Since at least May 15, 2023) | Director · Since at least Nov 7, 2019 |
| Steve O'Loughlin Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Chief Financial Officer · Sep 1, 2021 – Mar 31, 2025 · Past) | Chief Financial Officer · Since at least Mar 2, 2026 |
| Amy Mahery | Director · Since at least Nov 5, 2026 |
| Andrzej Andraczke | Director · Jul 15, 2021 – Sep 21, 2023 · Past |
| Carl Anthony Evans | Director · Nov 7, 2019 – Apr 8, 2024 · Past |
| Dylan Wenke | Chief Business Officer · Since at least Sep 1, 2026 |
| Eric Faulkner | Chief Technology Officer · Since at least Feb 17, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Jerzy Gumulka | Director · Since at least Nov 7, 2019 |
| Lynne Kelley | Chief Medical Officer · Since at least Mar 2, 2026 |
| Michal Fisher | Director · Since at least May 4, 2026 |
| Rami Levin | President & Chief Executive Officer · Since at least Jan 1, 2026 |
| Steve O’Loughlin | Chief Financial Officer · Since at least Aug 12, 2026 |
Log in to ask 6ix AI your own questions about CNS Pharmaceuticals, Inc.